PRINCETON, NJ, and OKLAHOMA CITY, OK--(Marketwired - February 15, 2016) - GtreeBNT Co., Ltd., has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) to acquire the rights ...
PRINCETON, N.J., July 19, 2021 /PRNewswire/ -- Oblato, Inc. (the Company) announced today that it has received an agreement from the FDA for its plan to submit an intermediate size expanded access ...
The U.S. National Science Foundation's Prototype Open Knowledge Network, or Proto-OKN, program invites you to attend a virtual office hour session. A Proto-OKN program director will host a group ...
OKN-007 is being evaluated both alone and in combination with chemotherapy for patients with glioma or glioblastoma — both types of brain cancer. Patients can now enroll in a phase 1 clinical trial ...
PRINCETON, N.J., Dec. 10, 2020 /PRNewswire/ -- Oblato, Inc. (the Company), a wholly owned U.S. subsidiary of the Korean biotech company GtreeBNT Co., Ltd., announced it had official discussions with ...
Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial. This is an ASCO Meeting Abstract from the 2020 ASCO ...
OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple ...
Below is a summary assembled by the Research & Innovation Office (RIO). Please see the full solicitation for complete information about the funding opportunity. This ...
All proposals must be submitted in accordance with the requirements specified in the funding opportunity and in the Proposal & Award Policies & Procedures Guide (PAPPG) and its supplements. All NSF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results